Volume 20, Number 3—March 2014
Concomitant Multidrug-resistant Pulmonary Tuberculosis and Susceptible Tuberculous Meningitis
To the Editor: In 2012, a 34-year-old HIV-seronegative man was hospitalized after several months of cough, fever, night sweats, 10-kg weight loss, and, in the past month, severe headache. The patient was born in Romania and had lived in France for 2 years. He had a history of pulmonary tuberculosis (TB) for which treatment was started in Romania in 2006 and 2008, but he did not complete treatment. The treatment he received in Romania was unknown.
At hospital admission, the patient had a fever of 39°C, stiff neck, and swollen cervical and axillary lymph nodes. A chest radiograph showed multiple cavities and nodular opacities in both superior lobes. Sputum auramine staining indicated that acid-fast bacilli was positive, which supported the diagnosis of pulmonary TB. Examination of cerebrospinal fluid (CSF) revealed hypoglycorrachia (0.95 mmol/L, concentration ratio CSF/blood: 0.2 [reference range 0.5–0.75]), hyperproteinorrachia (1.3 g/L [reference range 0.2–0.4 g/L]), erythrocyte count 2,000 μL (reference value <10 μL), and leukocyte count 150 μL (reference value <10 μL). Auramine staining showed no acid-fast bacilli in CSF. Standard antituberculous therapy with rifampin (RIF), isoniazid (INH), pyrazinamide, and ethambutol was started.
Genomic amplification–based assay (Xpert MTB/RIF; Cepheid, Maurens-Scopont, France), performed on sputum, confirmed the presence of the Mycobacterium tuberculosis genome and detected resistance to RIF (Table). The line probe assay Genotype MTBDRplus (Hain Lifescience, Bandol, France) performed on sputum showed a positive signal for all wild-type sequences and for rpoB (S531L associated with RIF resistance) and katG (S315T associated with INH resistance) mutations, suggesting the presence of mixed susceptible and resistant M. tuberculosis. Second-line treatment was started: moxifloxacin, amikacin, ethionamide, para-aminosalicylic acid, cycloserine and linezolid. The presence of mixed M. tuberculosis organisms in lungs was confirmed with culture methods and by phenotypic drug susceptibility testing (DST) that showed 1% resistant mutant to RIF and INH (proportion method) (1). The isolate was considered resistant to RIF and INH and was thus categorized as multidrug resistant (MDR). DST also showed that the sputum isolate had an elevated proportion of ofloxacin-resistant mutants (2 mg/L, 0.02% resistant mutants). Although no mutation in gyrA or gyrB was detected on colonies grown in the absence of fluoroquinolone, a gyrB N538D mutation was identified on colonies grown on ofloxacin medium. On the basis of the DST results, the treatment was changed to ethambutol, pyrazinamide, amikacin, moxifloxacin, para-aminosalicylic acid, and linezolid. CSF culture was eventually positive for M. tuberculosis on Lowenstein-Jensen medium after 30 days. DST performed on the CSF isolate showed a drug-sensitive phenotype; thus, RIF was reintroduced in addition to the other antimicrobial drugs. After 3 months, although the patient had improved, he left the hospital against medical advice without providing follow-up contact information.
Mycobacterial interspersed repetitive unit–variable number tandem repeat (MIRU-VNTR) analysis was conducted on culture of the sputum and CSF sample and on colonies grown on INH, RIF, and ofloxacin–containing medium, as described (2) (Table). This analysis showed different genotypes for the lung MDR and the CSF-susceptible isolates. None of the MIRU-VNTR patterns were linked to known lineages. The mutation rate of MIRU-VNTR has been evaluated at 2.7 × 10–3/loci/year (3). Rather than natural evolution of 1 strain, the 5-locus difference observed for the MIRU-VNTR genotypes is probably attributable to infection with 2 M. tuberculosis strains. Surprisingly, MIRU-VNTR patterns were identical for the gyrB mutated lung isolate and to the antimicrobial drug–susceptible isolate obtained from CSF. Also, the gyrB mutated lung isolate was susceptible to other antimicrobial drugs, whereas the lung MDR isolate did not harbor any gyrB mutation. Taken together, both genotype and DST heterogeneity were shown (Table). None of the drug-resistant clones were isolated in CSF.
This heterogenous infection raises 2 hypotheses: the patient was infected with both the MDR and the non-MDR strains or with 2 non-MDR strains and acquired additional drug resistance in the lung during treatment. Clonal differences among M. tuberculosis culture isolates obtained from pulmonary and CSF samples indicate compartmentalization (4). Heterogeneity in M. tuberculosis isolates already has been reported either for genotypes or for drug susceptibility (5–7). However, combination of genotype and resistance heterogeneity is a diagnostic and therapeutic challenge (8). In our laboratory, the line probe assay performed directly on sputum detected the 1% INH- and RIF-resistant mycobacteria, although a previous report suggest that this assay could not detect <5% resistant mycobacteria (9). The antimicrobial drug–resistant clones were isolated from only lung. The higher bacillary population in lungs than in central nervous system may account for an increased selection of resistant mutants in lungs. This finding raises the question of whether DST obtained from lung isolates should be used for establishing TB treatment at extrapulmonary localizations, especially in patients with meningitis, for whom effective treatment is an emergency. Because first-line treatments are more effective, we wonder whether treatment for MDR TB patients who have secondarily acquired resistance and both lung and central nervous system TB should target MDR and drug-susceptible TB until the CSF strain is proven to also be MDR.
- Canetti G, Rist N, Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation [in French]. Rev Tuberc Pneumol (Paris). 1963;27:217–72 .
- Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol. 2000;36:762–71 .
- Ragheb M, Ford C, Chase M, Lin P, Flynn J, Fortune S. The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosis from cynomolgus macaque infection. BMC Genomics. 2013;14:145–53 .
- García de Viedma D, Marín M, Ruiz Serrano MJ, Alcalá L, Bouza E. Polyclonal and compartmentalized infection by Mycobacterium tuberculosis in patients with both respiratory and extrarespiratory involvement. J Infect Dis. 2003;187:695–9.
- Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol. 2011;49:385–8 .
- Zhang X, Zhao B, Liu L, Zhu Y, Zhao Y, Jin Q. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J Clin Microbiol. 2012;50:1471–4.
- Van Rie A, Victor TC, Richardson M, Johnson R, Van der Spuy GD, Murray EJ, Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med. 2005;172:636–42.
- Cohen T, Van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev. 2012;25:708–19.
- Folkvardsen DB, Svensson E, Thomsen VØ, Rasmussen EM, Bang D, Werngren J, Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol. 2013;51:1596–9.
Suggested citation for this article: Bernard C, Brossier F, Fréchet-Jachym M, Morand PC, Coignard S, Aslangul E, et al. Concomitant multidrug-resistant pulmonary tuberculosis and susceptible tuberculous meningitis [letter]. Emerg Infect Dis [Internet]. 2014 Mar [date cited]. http://dx.doi.org/10.3201/eid2003.131205
- Page created: February 20, 2014
- Page last updated: February 20, 2014
- Page last reviewed: February 20, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)